Plain-English translation of NCT07223034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called lutetium-177-PSMA-617, which is a radioactive medication designed to target and treat certain brain tumors (gliomas) that have a specific marker called PSMA. Researchers want to find out if this medication is safe to give to patients after they've already had surgery and radiation therapy. The study will enroll about 20 patients and closely monitor their response to treatment.
Standard treatments for these types of brain tumors don't work well for all patients, and many people experience recurrence or progression of their disease. This trial exists to explore whether this medication could offer a new option for patients whose tumors express a specific marker, potentially improving their chances of controlling the cancer.
You likely qualify if…
You likely don't qualify if…
You would receive two cycles of the new radioactive medication, spaced out over time. Before each treatment, you would also take a chemotherapy pill called . Throughout the study, you would have MRI scans of your brain every 2 months to check how the treatment is working, and a special PET scan about 1 month after your second treatment. The study includes regular follow-up visits and monitoring to watch for any side effects and to see how well the treatment is controlling your tumor.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States